Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 176 participants.

Also called NCT06677970

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 176 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06677970
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06677970. Randomized; single masking; primary purpose treatment. Start 2024-10-01 (actual); primary completion 2029-12-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)
Condition
Acute Ischemic Stroke
Intervention (Drug)
BP lowering drugs (nicardipine, labetalol, urapidil)
Intervention (Drug)
BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct06677970
Content hash
9cdd2923ddc21c2eed75ad4c455c7db038e790ea47715c52c0d8c57cc7a96fc4